ADC Therapeutics, an oncology drug discovery and development company that specializes in the development of proprietary Antibody Drug Conjugates (ADCs) targeting major cancers, announced that it has raised USD 80 million through a private placement of equity. New investors include leading European and US-based investors alongside founding investor Auven Therapeutics and participation from AstraZeneca. ADCT was established in 2012 by private equity firm Auven Therapeutics.  In 2013, AstraZeneca/MedImmune acquired an equity stake in the Company and entered into a collaboration for two ADC programs.

Homburger acted as legal counsel to ADC Therapeutics. The team was led by partner Dieter Gericke (Corporate | M&A) and included partner Reto Heuberger (Tax) as well as associates Andreas Müller and Nadine Wahlquist (both Corporate | M&A) and Moritz Seiler (Tax).